← Back to Search

Photobiomodulation

Photobiomodulation Therapy for Mouth Sores from Bone Marrow Transplant

N/A
Recruiting
Led By Kentaro Ikeda, DDS, MPH
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥18 years
Planned to undergo myeloablative allogeneic HCT using FluBu4 conditioning and Tac-Mtx GVHD prophylaxis
Must not have
Participants who have a history of radiation therapy to the head and neck
Participants who are planned to receive palifermin for OM prevention
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 20 days
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a light therapy device called THOR LX2.3 with LED Lollipop to prevent painful mouth sores in patients undergoing a specific type of stem cell transplant. The therapy uses light to reduce inflammation and speed up healing inside the mouth. About 20 patients will receive this treatment during their chemotherapy and for a period afterward.

Who is the study for?
This trial is for adults over 18 who are about to receive a bone marrow transplant and have agreed to the study. It's not for those who've had photobiomodulation therapy recently, radiation on their head or neck, issues with light sensitivity, or will be treated with palifermin.
What is being tested?
The trial tests if a special LED device called THOR LX2.3 can prevent mouth sores in patients getting intense chemotherapy before a bone marrow transplant. Participants will use this LED Lollipop daily during treatment.
What are the potential side effects?
Potential side effects of using the LED Lollipop may include discomfort in the mouth or changes in taste sensation, but since it's non-invasive, serious side effects are unlikely.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I am scheduled for a specific bone marrow transplant with FluBu4 and Tac-Mtx.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had radiation therapy to my head or neck.
Select...
I am scheduled to receive palifermin for mouth sore prevention.
Select...
I have a history of reacting badly to sunlight.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~20 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 20 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Duration of severe Oral Mucositis

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: INTRAORAL PBMT IN PATIENTS UNDERGOING alloHCTExperimental Treatment1 Intervention
The research study procedures include: screening for eligibility and study treatment including daily PBMT and clinical evaluations. Participants will receive the study treatment daily from the start of conditioning chemotherapy to day +20, or discharge (if you are able to be discharged from the hospital prior to day +20), whichever occurs first -THOR LX2.3 with LED Lollipop

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for mouth sores, such as intraoral photobiomodulation therapy (PBMT), work by using specific wavelengths of light to penetrate tissues, which helps reduce inflammation and promote healing. This light stimulation reduces oxidative stress, enhances cellular energy production, and modulates inflammatory responses, leading to faster tissue repair and pain relief. For mouth sore patients, these mechanisms are important as they offer a non-invasive option to manage symptoms effectively and improve healing outcomes.
Simultaneous red and infrared light-emitting diodes reduced pain in individuals with temporomandibular disorder: a randomized, controlled, double-blind, clinical trial.

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,108 Previous Clinical Trials
357,217 Total Patients Enrolled
THOR Photomedicine LtdUNKNOWN
Kentaro Ikeda, DDS, MPHPrincipal InvestigatorBrigham and Women's Hospital

Media Library

THOR LX2.3 with LED Lollipop (Photobiomodulation) Clinical Trial Eligibility Overview. Trial Name: NCT05335434 — N/A
Intraoral Photobiomodulation Therapy Research Study Groups: INTRAORAL PBMT IN PATIENTS UNDERGOING alloHCT
Intraoral Photobiomodulation Therapy Clinical Trial 2023: THOR LX2.3 with LED Lollipop Highlights & Side Effects. Trial Name: NCT05335434 — N/A
THOR LX2.3 with LED Lollipop (Photobiomodulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05335434 — N/A
~4 spots leftby Jun 2025